Evidence map›Paper›PMID 26841047›Full record

ArticleMemorias do Instituto Oswaldo Cruz2016

A molecular platform for the diagnosis of multidrug-resistant and pre-extensively drug-resistant tuberculosis based on single nucleotide polymorphism mutations present in Colombian isolates of Mycobacterium tuberculosis.

Luz Maira Wintaco Martínez, Gloria Puerto Castro, Martha Inírida Guerrero

Open access · diamondAbstract readValidation Study
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Luz Maira Wintaco MartínezInstituto Nacional de Salud, Bogotá, Colombia.
Gloria Puerto CastroInstituto Nacional de Salud, Bogotá, Colombia.
Martha Inírida GuerreroInstituto Nacional de Salud, Bogotá, Colombia.
Instituto Nacional de Salud · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing a fast, inexpensive, and specific test that reflects the mutations present in Mycobacterium tuberculosis isolates according to geographic region is the main challenge for drug-resistant tuberculosis (TB) control. The objective of this study was to develop a molecular platform to make a rapid diagnosis of multidrug-resistant (MDR) and extensively drug-resistant TB based on single nucleotide polymorphism (SNP) mutations present in therpoB, katG, inhA,ahpC, and gyrA genes from Colombian M. tuberculosis isolates. The amplification and sequencing of each target gene was performed. Capture oligonucleotides, which were tested before being used with isolates to assess the performance, were designed for wild type and mutated codons, and the platform was standardised based on the reverse hybridisation principle. This method was tested on DNA samples extracted from clinical isolates from 160 Colombian patients who were previously phenotypically and genotypically characterised as having susceptible or MDR M. tuberculosis. For our method, the kappa index of the sequencing results was 0,966, 0,825, 0,766, 0,740, and 0,625 forrpoB, katG, inhA,ahpC, and gyrA, respectively. Sensitivity and specificity were ranked between 90-100% compared with those of phenotypic drug susceptibility testing. Our assay helps to pave the way for implementation locally and for specifically adapted methods that can simultaneously detect drug resistance mutations to first and second-line drugs within a few hours.

Indexed as

Antibiotics, AntitubercularColombiaDNA, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesGene AmplificationHumansIsoniazidMolecular Diagnostic TechniquesMutationMycobacterium tuberculosisNucleic Acid HybridizationPolymorphism, Single NucleotideRifampinSequence Analysis, DNATuberculosis, Multidrug-ResistantAntibiotics, AntitubercularDNA, BacterialFluoroquinolonesIsoniazidRifampin

Identifiers

PMID26841047
PMCPMC4750448
OpenAlexW2272356273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.